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ABSTRACT 
 
Kynurenic acid (KYNA) belongs to the kynurenines, a group of metabolically related 
compounds derived from the amino acid tryptophan. It is an antagonist of glutamate- and 
α7 nicotinic acetylcholine (α7nACh) receptors. Increased levels of KYNA have been 
observed in the cerebrospinal fluid and postmortem brains of patients with schizophrenia. 
An increased dopamine neurotransmission is suggested to underlie pivotal symptoms in 
schizophrenia and patients show an augmented dopamine response to amphetamine 
administration. Previous studies reveal that elevated levels of brain KYNA increase the 
firing activity of midbrain dopamine neurons. The aims of the present thesis were to 
investigate a) the receptors involved in the excitatory action of KYNA on midbrain 
dopamine neurons and b) the influence of elevated brain KYNA levels on the dopamine 
response to amphetamine.  
Single unit recording techniques and microdialysis were used for measuring dopamine 
firing and terminal efflux, respectively. The excitatory effects on ventral tegmental area 
(VTA) dopamine neurons observed in rats with elevated levels of KYNA were mimicked 
by administration of 4-chlorokynurenine (4-CL-KYN). This compound is transformed in 
situ to 7-CL-KYNA, which specifically blocks the glycine-site of the NMDA-receptor 
without affecting α7nACh receptors. Further, administration of the selective NMDA 
receptor antagonist SDZ 220-581 also increased dopamine firing, while administration of 
the selective α7nACh receptor antagonist methyllycaconitin (MLA) was associated with a 
decreased VTA dopamine firing. These results argue that the excitatory effect on midbrain 
dopamine neurons by elevation of brain KYNA, is specifically related to a blockade of 
NMDA receptors. 
Subchronic, but not acute, elevation of brain KYNA was associated with an enhancement 
of the amphetamine-induced dopamine response, with regard to both release and firing. 
This potentiated action of amphetamine on dopamine release appears related to an 
attenuated ability of the drug to inhibit firing of VTA dopamine neurons.  
Altogether, the present results support the hypothesis that increased levels of brain KYNA, 
potentiate the amphetamine response in VTA dopamine neurons primarily through a 
blockade of glutamatergic receptors, rather than cholinergic receptors. A reduced 
responsiveness of VTA dopamine neurons toward the inhibitory action of amphetamine 
might partly explain the excessive dopamine efflux occurring in a situation of elevated 
brain KYNA. Given the similarities in amphetamine response between patients with 
schizophrenia and rats with subchronically elevated levels of KYNA, one may propose that 
the latter condition may serve as a valuable animal model of schizophrenia.   
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1 INTRODUCTION 
 
1.1  Schizophrenia    
Schizophrenia was first identified as a discrete mental illness by Dr. Emil Kraepelin in 1887 and 
the illness itself is generally believed to having accompanied mankind through history.  The 
disease is among the most disabling and economically devastating medical disorders, ranked by 
the World Health Organization as one of the top ten illnesses contributing to the global burden of 
disease. It is a chronic and severe brain disorder that emerges independently of sex and ethnical 
origin, with a prevalence of approximately 0.55-0.87% (Goldner et al., 2002; Perälä et al., 2007). 
Despite extensive research, its etiology and pathophysiology is largely unknown. Though, it is 
clear that both genetic and environmental factors are involved in the development of the disease. 
The onset of schizophrenia is a gradual deterioration that usually occurs in adolescence and early 
adulthood and is usually initiated with acute psychotic symptoms. Those close to the patient may 
though advert early warning signs long before the primary symptoms occur. Non-psychotic 
premorbid signs of neurological and behavior problems during early years may appear, such as 
delayed development of speech and motor function, as well as social withdrawal and decreased 
IQ scores (Jones et al., 1994; Woodberry et al., 2008).  Average lifetime expectancy is 10-12 
years less in patients with schizophrenia and is mainly related to cardiovascular diseases and a 
higher suicide rate. Death as a consequence of suicide is about ten times more common in 
patients compared to the general population (Brown, 1997). Moreover, an increased risk for 
psychiatric comorbidity, including major depression and substance abuse is also observed.  
 
1.1.1  Symptoms 
The clinical symptoms of schizophrenia are often manifested in a set of symptoms that may vary 
over time and likewise, vary between patients. Symptoms are commonly divided into three broad 
clusters, i.e. positive symptoms, negative symptoms and cognitive deficits (Andreasen, 1995). 
Positive symptoms, commonly referred to as psychotic symptoms, typically emerge as delusions 
and hallucinations and refer to features that appear. A delusion appears like an unshakable theory 
or belief in something false and impossible despite evidence of the contrary, often including 
Alexandra Andersson 
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persecutory delusions involving bizarre ideas that someone is “out to get” the patient. A 
hallucination refers to a sensation or a sensory perception, which a person experiences in the 
absence of a relevant external stimulus. It can occur in any sensory modality (visual, auditory, 
olfactory, gustatory, tactile), although auditory hallucinations (hearing voices or some other 
sound) are the most common type of schizophrenia. Positive symptoms commonly also include 
some level of disorganized thinking and speech that often results in “word salad” or incoherent 
and incomprehensible speech.  
Negative symptoms refer to a loss or absence of normal traits or abilities that healthy people 
normally own. Common negative symptoms include affective flattening, where the patient’s 
range of emotional expression is clearly diminished, such as poor eye contact and reduced body 
language. Likewise, anhedonia (inability to experience pleasure), lack of motivation and poverty 
of speech, such as brief, empty replies frequently appear (Andreasen, 1995). Cognitive 
dysfunctions are related to impairments in thought processes, including a broad range of features 
where the patient displays difficulties in problem solving and abstract thinking. Correspondingly, 
deficit in memory and attention as well as poor judgment commonly emerge (Green et al., 2000). 
Positive symptoms are commonly episodic and vary over the course of the illness. The negative 
and cognitive symptoms appear to be more persistent over time, although a general decline of 
cognitive functions are associated with the time of onset of the illness (Mesholam-Gately et al., 
2009; Sponheim et al., 2010). Predictors of poor treatment outcome are male gender, severity of 
negative symptoms and cognitive deficits, early age of onset as well as prolonged period of 
untreated illness (Perkins et al., 2005). 
 
1.1.2  Treatment 
Although an important element, antipsychotic drugs are far from the only treatment used for 
patients with schizophrenia. Commonly, supplemental therapies such as psychosocial or 
cognitive therapy are used in conjunction with drugs. In certain severe cases, some patients also 
respond to electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS). These 
additional treatments can be essential for a full recovery, although antipsychotic drugs are the 
best tool right now for controlling symptoms, particularly the positive ones. The discovery of the 
antipsychotic properties of chlorpromazine (Delay et al., 1952) initiated new treatment options 
Introduction 
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and the development of antipsychotic medications constituted the primary pharmacological tool 
for the treatment of patients with schizophrenia. 
 
1.1.3  Typical antipsychotics 
The first generation of antipsychotic drugs (e.g. chlorpromazine and haloperidol) is often referred 
to as typical antipsychotic drugs. Generally these drugs reduce positive symptoms, whereas 
usually minor or no effects on negative and cognitive symptoms are generated (King, 1998). The 
clinical effects of the typical antipsychotics are generally believed to be due to their ability of 
blocking dopamine D2 receptors. Typical antipsychotic drugs are also associated with a relative 
high incidence of extrapyramidal side effects (EPS), such as akathisia (inner restlessness and a 
compelling need to be in constant motion), parkinsonism (tremor, rigidity, akinesia) and tardive 
dyskinesia (involuntary stereotypical movements of the mouth, face and tongue) (Marsden and 
Jenner, 1980).  
 
1.1.4  Atypical antipsychotics 
Atypical antipsychotics usually require lower occupancy of dopamine D2 receptors, with broader 
receptor profile and most of them own a high affinity for 5-HT2A receptors. Most atypical 
antipsychotics may not induce EPS at the same extent as typical antipsychotics but instead induce 
other severe adverse effects, such as heavy sedation and weight gain as well as insulin resistance, 
which may lead to diabetes and cardiovascular diseases. Clozapine is the most effective agent for 
the treatment of schizophrenia and is considered especially effective in patients with treatment-
resistant schizophrenia and unlike other antipsychotics, owns the property of treating also 
negative and cognitive symptoms (Conley, 1998). In addition, clozapine produces few or no EPS 
(Walker et al., 1997). It is also the only antipsychotic drug with a demonstrated significant 
reduction in suicidality. The side-effect agranulocytosis has however limited its use. 
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1.2   HYPOTHESES OF SCHIZOPHRENIA 
1.2.1   The dopamine hypothesis of schizophrenia 
When the dopamine hypothesis of schizophrenia was initially proposed 50 years ago, it 
postulated that schizophrenia is a manifestation of a hyperdopaminergic state in the brain 
(Carlsson and Lindqvist, 1963). The foundation of this hypothesis was mainly built on indirect 
pharmacological evidence and the discovery that antipsychotic drugs increase dopamine 
metabolism in animals and that the clinical effectiveness of these drugs, was directly correlated 
with their potency to block dopamine D2 receptors (Seeman and Lee, 1975). Conversely, 
following heavy doses or long-term administration, drugs that increase dopaminergic activity, 
such as amphetamine, can induce psychosis in healthy volunteers, (Snyder, 1973) and generally 
worsen symptoms in patients with schizophrenia (Snyder et al., 1974). Yet, for many patients the 
hypothesis fits poorly, particularly for those whose symptoms come on gradually and where the 
negative and cognitive symptoms are more prominent than the positive (Andreasen and Olsen, 
1982). These patients also appear to be more resistant to treatment with antipsychotic drugs 
(Demjaha et al., 2012). Furthermore, the whole spectra of schizophrenia-like symptoms are rarely 
induced in healthy individuals when exposed to dopamine enhancing drugs (Snyder, 1973). 
The inconsistency of the accumulated data commanded a modification of the dopamine 
hypothesis. Thus, a regional dopamine reactivity was suggested, where a specific prefrontal 
hypofunction due to deficits in D1 receptor-mediated signaling contributed to the negative 
symptoms and cognitive impairments, whereas an intermittent excess in subcortical dopamine 
hyperfunction involving D2 receptors was related to the emergence of psychotic states (Davis et 
al., 1991). This “dopamine imbalance theory” predominantly relied on animal studies and there 
was no direct evidence supporting either low dopamine levels in prefrontal cortex or enhanced 
subcortical levels of dopamine in patients with schizophrenia (Howes and Kapur, 2009). 
Subsequently it has become clear that these abnormalities are more complex and neuroimaging 
studies have revealed additional data, indicating an elevated presynaptic dopamine synthesis 
capacity in patients with schizophrenia (Hietala et al., 1995; Lindstrom et al., 1999).  
Neurochemical models of schizophrenia based upon dopamine have had substantial empirical 
value in explaining key symptoms of schizophrenia, in particular the progress of positive 
Introduction 
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symptoms. Nevertheless, significant limitations with regard to the dopamine hypothesis remains 
and the underlying pathophysiology of schizophrenia may additionally involve other 
neurochemical systems. An alternative hypothesis reveals that symptoms in schizophrenia may 
reflect an underlying dysfunction or dysregulation in glutamatergic systems (Javitt, 2010).  
 
1.2.2  The glutamate deficiency hypothesis of schizophrenia 
The glutamate deficiency theory of schizophrenia proposes a hypofunction in glutamatergic 
transmission and is based on the findings that glutamate levels are decreased in the cerebrospinal 
fluid (CSF) of patients with schizophrenia (Kim et al., 1980). The “PCP model of schizophrenia” 
was formed upon the observation that drugs, blocking the N-methyl-D-aspartate (NMDA) 
receptor, such as phencyclidine (PCP), ketamine and other similar psychotomimetic compounds, 
possess the unique potential to reproduce the full symptomatic spectra of schizophrenia, in 
healthy individuals (Javitt and Zukin, 1991; Lahti et al., 2001). Compared to dopaminergic agents 
like amphetamine, which only induces psychoses (Snyder, 1973), PCP and ketamine provokes 
positive and negative symptoms, as well as the cognitive deficits (Javitt, 1987; Javitt and Zukin, 
1991). Symptoms are also exaggerated or reawaken in patents with schizophrenia (Lahti et al., 
2001; Malhotra et al., 1997). Further, brain imaging studies in humans reveal that ketamine 
administration to healthy individuals, increase striatal dopamine levels and potentiates the 
amphetamine-induced dopamine response, similar as in patients suffering from schizophrenia 
(Kegeles et al., 2000; Breier et al., 1997). 
At the neurochemical level, PCP and ketamine interact with the PCP site of the NMDA receptor. 
Occupation of this specific site induces non-competitive inhibition of NMDA receptor-mediated 
transmission (Javitt and Zukin, 1991). A relationship regarding the dopamine hypothesis and the 
glutamate deficiency theory has been proposed. Thus, NMDA receptors regulate dopamine 
release. In particular, it is shown that longterm administration of NMDA receptor antagonists 
increase midbrain dopamine transmission (Jentsch et al., 1998) and decrease prefrontal cortex 
dopamine transmission concomitant with cognitive impairments in both rats (Jentsch et al., 
1997b) and monkeys (Jentsch et al., 1997a). The regional dopaminergic imbalance seen in 
schizophrenia may thus be secondary to an underlying glutamatergic dysfunction (Javitt, 2007). 
In the midbrain, gamma-amino-butyric-acid (GABA) neurons exert an inhibitory influence on 
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dopaminergic neurons (Erhardt et al., 2002). The enhancement of midbrain dopamine 
transmission following NMDA receptor antagonism, is hypothesized to be a consequence of 
decreased excitatory influence on GABA interneurons, relieving dopamine neurons in the ventral 
tegmental area (VTA) from this source of inhibitory tone (Zhang et al., 1993).  
The glycine modulatory site of the NMDA receptor complex has been suggested as a promising 
target, although much research in this area is still needed. Thus, several clinical studies in patients 
with schizophrenia revealed beneficial effects on negative and cognitive symptoms when glycine 
was added to conventional antipsychotic treatment (Coyle and Tsai, 2004). Furthermore, 
complement of the potent full agonist D-serine, have also been shown to relieve positive 
symptoms (Tsai et al., 1998). These agents, including the anti-tuberculosis drug D-cycloserine, 
have also proven to be effective in several preclinical models, including reversal of PCP effects in 
both rodents (Javitt et al., 2004) and primates (Linn et al., 2007). Additionally, the antipsychotic 
drug clozapine, known for its superior efficacy in alleviating symptoms of schizophrenia, has 
been shown to retain partial agonistic properties at the glycine site of the NMDA receptor 
(Schwieler et al., 2008). 
 
1.2.3  The kynurenic acid hypothesis of schizophrenia 
Kynurenic acid (KYNA) was first discovered for more than 150 years ago (Liebig et al., 1853) 
and has been proven to retain important implications for the neurosciences. KYNA is synthesized 
by astrocytes and belongs to the kynurenines, a group of metabolically related compounds 
derived from the essential amino acid tryptophan (Leklem, 1971). The kynurenine pathway is the 
main route of tryptophan degradation, containing several enzymatic steps and responsible for 
approximately 95% of the metabolic breakdown of tryptophan (Schwarcz et al., 2012).   
The kynurenine pathway is initiated through transformation of tryptophan into N-
formylkynurenine by the enzyme indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-
dioxygenase (TDO). N-formylkynurenine is further degraded by formamidase into kynurenine, 
the pivotal compound of the kynurenine pathway, which can be metabolized in three different 
routes (Schwarcz et al., 2012: see figure). To ultimately form KYNA, kynurenine undergoes 
irreversible transamination by four different kynurenine aminotransferases (KATs), where KAT 
II is suggested to be the main catabolic enzyme of KYNA in humans (Guidetti et al., 2007). 
Introduction 
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The kynurenine pathway 
 
Neurochemically, KYNA is an antagonist of glutamate receptors, inhibiting all three ionotropic 
excitatory receptors, (e.g. NMDA-, kainate- and AMPA receptors) (Perkins and Stone, 1982). 
KYNA has a greater affinity for the obligatory glycine co-agonist site of the NMDA receptor, 
thus this glycine site constitutes a preferred molecular target (Parson et al., 1997). Owing to the 
competitive nature of the action of KYNA at this site, selective glycine receptor antagonists can 
substitute for KYNA (Maj et al., 1994), whereas agonists may counter the actions of KYNA 
(Birch et al., 1988; Russi et al., 1992). Furthermore, KYNA possesses antagonistic properties at 
the α7 nicotinic acetylcholine (α7nACh) receptor and the importance of an intact α7nACh 
receptor in cognitive processes, has been demonstrated in several studies during recent years 
(Albuquerque et al., 2009). Additionally, KYNA is known to exert neuroprotective properties 
against other kynurenine pathway metabolites, such as quinolinic acid and those of other 
excitotoxins (Zádori et al., 2012). The possibility of its therapeutic use therefore emerges 
regarding treatment of disorders in the central nervous system. Elevation of KYNA levels causes 
alterations in glutamatergic, cholinergic, and dopaminergic transmission, neurotransmitters 
frequently associated with symptoms of schizophrenia (Schwarcz et al., 2012). Recently, KYNA 
Quinolinic acid 
Kynurenine 
3-monohydroxylase 
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3-Hydroxykynurenine 
Anthranilic acid 
5-HT 
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also has been shown to posses regulating properties of GABA transmission (Beggiato et al., 
2013; Beggiato et al., 2014). The “Kynurenic acid hypothesis of schizophrenia” derives from the 
findings that KYNA is elevated in the CSF (Erhardt et al., 2001) and postmortem brain 
(Schwarcz et al., 2001) of patients with schizophrenia. These observations were later supported 
by studies displaying elevated KYNA levels in the CSF in drug naïve and drug-treated patients 
(Nilsson et al., 2005; Linderholm et al., 2012) as well as in the post mortem brain 
(Sathyasaikumar et al., 2011) of other cohorts. 
The relevance of elevated KYNA levels in the pathophysiology of schizophrenia has been 
maintained in several clinical and preclinical studies. Increased levels of midbrain dopamine 
concentrations are suggested to be involved in the creation of positive symptoms. In line with 
administration of  exogenous NMDA receptor antagonists PCP and MK801 (French et al., 1993), 
KYNA increases the firing rate of midbrain dopamine neurons (Erhardt and Engberg, 2002; 
Nilsson et al., 2006). The opposite condition occurs when the levels of KYNA is reduced, leading 
to decreased firing rate of dopamine neurons (Schwieler et al., 2006) suggesting that KYNA 
owns the property to exert tonic regulation of midbrain dopamine neurons. 
During the past decade the kynurenic acid hypothesis has been strengthened by a large number of 
experimental studies also, giving a robust support for the physiological significance of KYNA. 
Recent studies suggest that KYNA bi-directionally influences cortical and hippocampal 
glutamate release (Konradsson-Geuken et al., 2010) as well as modulates acetylcholine release 
(Zmarowski et al., 2009). Cognitive dysfunctions, such as impaired working memory and verbal 
learning are common in patients with schizophrenia. In experimental studies, pharmacologically 
elevated levels of KYNA reduce cortical and hippocampal levels of glutamate and cause 
impairment in visuospatial working memory and contextual learning memory in rodents (Chess 
and Bucci, 2006; Konradsson-Geuken et al., 2010). Prepulse inhibition (PPI), a behavior test of 
sensorymotor gating is further impaired in animals with elevated KYNA levels (Erhardt et al., 
2004). 
Endogenous KYNA emerges to control and regulate several transmitters, important for optimal 
brain functioning. Further research concerning the synthesis and influence of KYNA on various 
neurotransmitter systems, may provide new perspectives and bring light to new possibilities of 
developing better pharmacological tools in the treatment of schizophrenia. 
Specific aims of the study 
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2 SPECIFIC AIMS OF THE STUDY 
 
1. To study the mechanism involved in the excitatory action of elevated levels of 
endogenous kynurenic acid on VTA dopamine firing. 
 
2. To examine the influence of elevated brain kynurenic acid on amphetamine-
induced dopamine transmission.  
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3 MATERIALS AND METHODS 
 
3.1    ANIMALS  
Male Sprague–Dawley rats (Scanbur BK, Sollentuna, Sweden) weighing minimally 180 g (at 
time of mini-pump implantation) and maximally 250 g (at the time of the experiment) were 
housed in groups of 3–4. Free access to food and water was provided. Environmental conditions 
were checked daily and maintained under constant temperature (25 °C) and humidity (40–60%) 
in a room with a regulated 12-h light/dark cycle (lights on 06:00 hours). Experiments were 
approved by and performed in accordance with the guidelines of the Ethical Committee of 
Northern Stockholm, Sweden. All efforts were made to minimize the number of animals used and 
their suffering.  
 
3.2   SURGERY 
To subchronically elevate endogenous KYNA concentration, rats were administered kynurenine 
for 6 d via two osmotic minipumps (volume 2 ml) with continuous flow of 10 µl/h. The osmotic 
pumps (2ML1 Alzet®, Cupertino, CA, USA) were filled under aseptic conditions with either 
vehicle (0.9% NaCl) or kynurenine (dissolved in deionized water; pH adjusted to 5.7 with 
NaHCO3) in a concentration equivalent to a dose of 90 mg/kg/d (at day of implantation). All 
solutions were passed through a sterile filter (Acrodisc Syringe Filter 13 mm with 0.2 µm 
Supor® membrane) before the filling of pumps. Rats were anaesthetized in a Plexiglas chamber 
filled continuously with 4.8% isoflurane in air using a vaporizer (Univentor 400 Anaesthesia 
Unit; Univentor Ltd, Zejtun, Malta) and positioned on a heating pad maintaining body 
temperature at 37 °C throughout the surgery (Temperature Control Unit, HB 101/2, AgnTho’s 
AB, Lidingö, Sweden). Anesthesia was maintained using a nose cone delivering 2.4% isoflurane. 
Before surgery, 0.5 ml bupivacain (5 mg/ml) was administered subcutaneously (s.c.) to provide 
post-operative analgesia. The osmotic minipumps were inserted through an incision in the neck 
and placed s.c. on the back of the rats. To verify an effect of the kynurenine administration on 
KYNA concentration, blood was collected from the lateral tail vein at the end of surgery. These 
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samples were then compared with blood collected at day 6. After surgery rats were placed in 
single cages for 24 h before being reunited in groups of three. After 6 d, electrophysiological or 
microdialysis experiments were performed.  
 
3.3   ELECTROPHYSIOLOGY 
In electrophysiological experiments, rats were anaesthetized (chloral hydrate; 400 mg/kg i.p.) and 
mounted onto the ear bars of a conventional stereotaxic frame (David Kopf Instruments, Tujunga, 
CA, USA) so that the skull was set in a horizontal plane and the nose was secured using a clamp 
at the front of the frame. For i.v. administration, a cannula was inserted into a lateral tail vein and 
additional injections of chloral hydrate were given as needed to maintain a stable level of 
anesthesia. Drugs were also given through a lateral tail vein. Throughout the experiments, the 
body temperature of the animals was maintained at 37 oC by means of a thermostatic heating 
pad. The skull surface was exposed and a 3 mm burr hole was drilled with its center located 
approximately 3.0 mm anterior to the lambda and 0.7 mm lateral to the midline. Following 
careful removal of the dura, a glass microelectrode with a tip diameter of approximately 1-2 µm 
(filled with 0.5 M sodium acetate saturated with Pontamine Sky Blue) was lowered by means of a 
hydraulic micro drive (David Kopf Instruments, Tujunga, CA, USA) in to the region of VTA, 
according to the stereotaxic coordinates from the atlas of Paxinos and Watson (1998). The in 
vitro impedance of the electrode was generally 6-8 MΩ, measured at 135 Hz in 0.9% saline. 
Single unit potentials were passed through a high input-impedance amplifier and filters. The 
impulses were discriminated from background noise and fed into a computer, and simultaneously 
displayed on a digital storage oscilloscope, monitored on an audio monitor and on a strip chart 
recorder (Gould). All dopamine neurons were found 7.5-8.5 mm from the brain surface and 
fulfilled the neurophysiological characteristics (i.e. triphasic action potentials with a duration 
more than 2.0 ms, basal firing rates between 1 and 10 Hz and frequent occurrence of burst firing 
including progressively decreasing spike amplitude) previously described for dopamine neurons 
in the VTA (Grace and Bunney, 1984a,b). The inhibitory response to aversive stimuli (foot 
pinch) was also observed (Ungless et al., 2004). To further confirm that recordings had been 
made exclusively from dopamine neurons, the inhibitory action of a single dose of the dopamine 
agonist apomorphine (100 µg/kg, i.v.) was verified at the end of the experiments when 
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experiments allowed. Immediately after each electrophysiological experiment the rats were 
decapitated. Brains were rapidly removed and stored immediately at -70 0C for subsequent 
analysis of KYNA and 7-Cl-KYNA. 
 
3.3.1   Experimental protocol for electrophysiological experiments in study I   
In the first series of experiments, the firing activity of VTA dopamine neurons was analyzed 1-
3.5 h after i.p. pretreatment with kynurenine or 4-Cl-KYN, by recording from a number of cells 
in each rat. The number of spontaneously firing VTA dopamine cells in the right hemisphere was 
calculated from the numbers of cells found per track (2-10 tracks per animal). The electrode was 
moved 0.1 mm between each track in a pattern to assure that cells were recorded from only once. 
No changes in firing pattern or in number of spontaneously active cells were observed with 
regard to the track number. In the second series of experiments the firing activity of VTA 
dopamine neurons was continuously monitored before, during and after i.v. injection of MLA or 
SDZ 220-581. 
 
3.3.2    Data analysis of electrophysiological characteristics 
The distribution of spikes was analyzed on line utilizing a Spike II software program. In order to 
avoid artifacts in the sampling procedure, the program was set to ignore time intervals below 20 
ms. The onset of a burst was determined as an inter-spike interval shorter than 80 ms and the 
termination of a burst by the next interval longer than 160 ms (Grace and Bunney, 1984a,b). Cells 
were considered to be bursting if at least one interspike time interval of 100 recorded spikes was 
below 80 ms. The interspike time intervals were analyzed with regard to the percentage of spikes 
fired in bursts that occurred during a sampling of 100–500 spikes. 
 
3.4   MICRODIALYSIS 
Rats were anaesthetized as described above and mounted into a stereotaxic frame 
(Stoelting,Wood Dale, Il., USA). Before each guide cannula implantation the incisor bar was 
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adjusted so that the skull was set in a horizontal flat plane. Anesthesia was maintained using a 
nosecone, delivering 2.4% isoflurane throughout the surgery. The skull was exposed, and two 
shallow holes were drilled for insertion of anchor screws. A hole was drilled above the nucleus 
accumbens and following careful removal of the dura a guide cannula (MAB 9.IC, AgnTho’s 
AB) was directed to the region of nucleus accumbens and fixed with stainless-steel screws and 
dental cement (Dentalon®, AgnTho’s AB). Stereotaxic co-ordinates for the implantation of the 
guide cannula with reference to bregma and brain surface, respectively, were: AP +1.6, ML ±1.4, 
DV +6.2, meaning that the tip of the guide cannula was placed 2 mm above the vertical target for 
the final position of the microdialysis probe (Paxinos and Watson, 1998). Following surgery, 0.5 
ml bupivacain (5 mg/ml) was administered s.c. to provide post-surgical analgesia. Rats were then 
allowed to recover, singly housed, for 24 h with food and water ad libitum.  
On the day of experiment, microdialysis was performed in unanaesthetized freely moving rats. 
The guide was removed and a microdialysis probe (MAB 9.14.2, polyether sulphone, 2 mm 
dialysing length, 0.56 mm diameter and a 15 kDa cut-off membrane; AgnTho’s AB) was inserted 
into the cannula. Rats were connected to microdialysis swivels. The probes were perfused with 
perfusion fluid CNS (CMA Microdialysis AB, Solna, Sweden) delivered via polyethylene tubing 
from an infusion pump (Univentor 864, Univentor Ltd) at a flow rate of 2 µl/min for dopamine 
analysis (in paper I Olsson), or 1 µl/min for KYNA/7-Cl-KYNA analysis (in paper II 
Linderholm). Thirty-minute fractions were collected using a microfraction collector (Univentor 
820, Univentor Ltd) and manually injected (Rheodyne, Cotati, CA, USA) into a high-
performance liquid chromatography (HPLC) system. To minimize the inter-individual variation 
due to differences in probe recovery, the dialysate concentrations were transformed to percent of 
baseline before statistical analysis. A stable baseline, consisting of three consecutive samples with 
a maximal variation of 10%, was usually obtained after 2–3 h and defined as 100%. Results for 
subsequent samples were calculated as percentages of this average basal release. In study II 
(Olsson), all rats were administered d-amphetamine intraperitoneally (i.p.) once a stable 
dopamine baseline was established and the dopamine concentration was measured for 180 min. 
One group of rats was pretreated with a single dose of kynurenine (5 mg/kg s.c.) 60 min prior to 
the microdialysis experiment and another group of rats were treated with kynurenine for 6 days 
(90 mg/kg/day) prior to the experiment.   
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In study I (Linderholm), rats were divided in two groups and administered with kynurenine (200 
mg/kg, s.c., n = 10) or 4-Cl-KYN (25 mg/kg, s.c., n = 6) respectively, prior to the microdialysis 
experiment (as described above). Concentrations of in situ produced 7-Cl-KYNA and KYNA 
were measured in 30 or 40 min fractions, for 210 or 240 min respectively, to verify the effect of 
respectively precursor.  
 
3.5   HISTOLOGY 
At the end of the microdialysis experiment, rats were decapitated and brains rapidly removed and 
stored in 4% paraformaldehyde in phosphate buffer for at least 5 d. Serial coronal sections (50 
µm) were made using a cryostat (Slee Medical GmbH, Mainz, Germany), and histological 
verification of probe placement was confirmed with reference to the stereotaxic atlas of Paxinos 
and Watson (1998). No distinction could be made between the core and the shell of the nucleus 
accumbens. Data are reported only from animals where probe membranes were correctly 
positioned in the nucleus accumbens.  
 
3.6   ANALYSIS OF DOPAMINE 
Separation of dopamine was achieved by reversed-phase liquid chromatography using a 55 mM 
sodium acetate buffer (pH 4.1, 10% methanol) with 0.8 mM octanesulfonic acid and 0.01 mM 
Na2EDTA. The mobile phase was delivered by an HPLC pump (Bischoff Chromatography, 
Leonberg, Germany) through a ReproSil-Pur C18 column (4 × 150 mm, Dr Maisch GmbH, 
Ammerbuch, Germany) at a rate of 0.8 ml/min. Following separation, the analysate was first 
passed through a guard cell with an oxidizing potential of 50 mV. Samples were then quantified 
by sequential oxidation and reduction in a high-sensitivity analytical cell (ESA 5011; ESA Inc., 
Chelmsford, MA, USA) controlled by a potentiostat (Coulochem III; ESA Inc.) with an applied 
potential -200 mV for detection of dopamine. The signals from the detector were transferred to a 
computer for analysis (Datalys Azur, Grenoble, France). The retention time of dopamine was 
approximately 8 min. 
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3.7   PREPARATION OF BRAINS AND BLOOD FOR KYNA ANALYSIS 
Brains were sonicated with homogenization medium (perchloric acid 0.4 M, Na2S2O5, 0.1% and 
ethylene-diaminetetra-acetate (EDTA) 0.05%), which was added in the same amount as the 
weight of the brain before sonication. The samples were centrifuged at 20,000 g for 5 min, and 40 
µl perchloric acid (70%) was added to the supernatant. Thereafter, the supernatant was 
centrifuged twice. Blood samples were centrifuged two times at 20 000 g for 5 min and 100 µl 
perchloric acid (70%) was added to the supernatant. Thereafter, the supernatant was centrifuged 
three times and stored at -18°C. Before analysis, samples were defrosted and one more time 
centrifuged. 
 
3.8   ANALYSIS OF KYNURENIC ACID AND 7-CHLORO-KYNURENIC ACID 
For analysis of KYNA and 7-Cl-KYNA, an isocratic reversed- phase high-performance liquid 
chromatography (HPLC) system was used, including a dual piston, high liquid delivery pump 
(Bischoff, Leonberg, Germany), a ReproSil-Pur C18 column (4 × 150 mm, Dr Maisch GmbH, 
Ammerbuch, Germany) and a fluorescence detector (Jasco Ltd, Hachioji City, Japan) with an 
excitation and emission wavelength of 344 nm and 398 nm, respectively (18 nm bandwidth). A 
mobile phase of sodium acetate (50 mM, pH 6.20, adjusted with acetic acid) and acetonitrile (7% 
or 10.0%, for KYNA or 7-Cl-KYNA, respectively) was pumped through the reversed-phase 
column at a flow rate of 0.5 ml/min. Samples of 30 ml were manually injected (Rheodyne, Cotati, 
CA, USA). Zinc acetate (0.5 M, not pH adjusted) was delivered post column by a peristaltic 
pump (P-500, Pharmacia, Uppsala, Sweden) at a flow rate of 0.10 ml/h. The signals from the 
fluorescence detector were transferred to a computer for analysis utilizing Datalys Azur 
(Grenoble, France). The retention time of KYNA or 7-Cl-KYNA was about 7 or 16 min, 
respectively.  
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3.9   STATISTICAL ANALYSIS 
The statistical software package GraphPad Prism® 4.03 (GraphPad Software Inc., San Diego, 
CA, USA) was used. All data are expressed as mean ±S.E.M. In paper II, no differences between 
the naive control groups and the groups treated with saline for 6 d were observed in either of the 
tested parameters. For ease of presentation, all control data presented, were pooled into one 
control group. Dopamine release is presented as the percent of baseline and the effect of 
amphetamine administration on dopamine release is analyzed using one-way analysis of variance 
(ANOVA), compared to predrug value, or two-way ANOVA for repeated measures (time × 
treatment) followed by Bonferroni post-hoc test. Statistically significant differences in 
electrophysiological experiments and with regard to concentration of blood and whole brain 
KYNA, were established using Kruskal-Wallis analysis of variance followed by Mann-Whitney 
U-test. Differences in percent spikes fired in bursts, were established using Kruskal-Wallis 
analysis of variance followed by Mann-Whitney U-test or Wilcoxon signed rank test. 
Significance was assumed for all values where P < 0.05. 
 
3.10   DRUGS AND CHEMICALS 
The following drugs were used: chloral hydrate (Merck, Darmstadt, Germany), L-kynurenine 
sulfate salt (Sigma, St Louis, MO, USA), KYNA, d-amphetamine sulphate (Apoteksbolaget, 
Goteborg, Sweden); 4-Cl-KYN (kindly supplied by Vistagen Therapeutics, South San Francisco, 
CA, USA and dissolved in 7.5% (2-hydroxypropyl)-β-cyclodextrin); 7-Cl-KYNA and SDZ 220-
581 (Tocris, Avonmouth, UK); isoflurane (Forene®, Abbott Scandinavia, Solna, Sweden); and 
MLA (Sigma, St.Louis,MO,USA). Chemicals used were as follows: zinc acetate, acetic acid 
(Sigma, St. Louis, MO, USA); pontamine sky blue (BDH Laboratory Supplies, UK), methanol, 
octanesulfonic acid, Na2EDTA (Sigma), sodium acetate (Riedel-de Haen, Germany), perchloric 
acid (Kebo Laboratory, Stockholm, Sweden), and acetonitrile (Labasco, Partille, Sweden). 
Perfusion fluid composition (CMA Microdialysis AB, Solna, Sweden): NaCl, 147.0; KCl, 2.7; 
CaCl, 1.2; and MgCl2, 0.85 (mM). 
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4      RESULTS AND DISCUSSION 
 
4.1     PAPER I: ACTIVATION OF RAT VENTRAL TEGMENTAL AREA DOPAMINE 
NEURONS BY ENDOGENOUS KYNURENIC ACID: A PHARMACOLOGICAL 
ANALYSIS 
Several studies reveal that elevated brain levels of endogenous KYNA increase firing of rat VTA 
dopamine neurons (Erhardt et al., 2001; Erhardt and Engberg, 2002; Nilsson et al., 2006; 
Schwieler et al., 2006). 
Study I aimed to investigate the specific receptors involved in the excitation of VTA dopamine 
neurons, following pharmacologically elevated levels of endogenous KYNA. A series of 
electrophysiological experiments were used to examine the firing rate and burst firing activity of 
VTA dopamine neurons, following administration of selective antagonists at different KYNA 
inhibition sites. The synthetic compound 4-chlorokynurenine (4-Cl-KYN) is transformed in situ 
into 7-Cl-KYNA, a highly selective antagonist at the glycine-site of the NMDA receptor. It 
shares this property with KYNA (Hokari et al., 1996), but do not antagonize the α7nACh 
receptor. Further, methyllycaconitine (MLA), an antagonist of the α7nACh receptor, and the 
competitive NMDA receptor antagonist SDZ 220-581 were analyzed regarding the firing pattern 
of VTA dopamine neurons. Concentrations of in situ produced KYNA and 7-Cl-KYNA were 
measured utilizing microdialysis techniques in nucleus accumbens, following systemic 
administration of kynurenine or 4-Cl-KYN (Fig 1). Firing of VTA dopamine neurons was 
monitored 1 – 3.5 h after kynurenine (200 mg/kg, i.p.), 4-Cl-KYN (25 mg/kg, i.p.) or saline 
administration respectively. Pretreatment with kynurenine as well as with 4-Cl-KYN was 
associated with an increase in firing rate and burst firing activity (Table 1). Further, the number of 
dopamine cells found per track was almost doubled following administration of 4-Cl-KYN, 
indicating an activation of dopamine neurons that may be quiescent under normal conditions.  
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Figure 1. Concentrations of in situ produced 7-Cl-KYNA and KYNA were measured utilizing microdialysis 
techniques in nucleus accumbens, after systemic administration of 4-Cl-KYN (25 mg/kg, s.c., n=6; Fig. 1a) 
or kynurenine (200 mg/kg, s.c., n=10; Fig. 1b). Each value represents mean ± SEM. 
 
Administration of the competitive NMDA receptor antagonist SDZ 220-581 (10 mg/kg, i.v.) was 
associated with an increase in firing rate of VTA dopamine neurons. The increase in frequency 
was typically not observed until 5 min after administration (Figures 2, 3a). Burst firing was 
increased 5 min after administration but not after 1, 10, 15 or 20 min (data not shown). A lower 
dose of SDZ 220-581 (5 mg/kg i.v.) failed to alter firing rate or burst firing activity of VTA 
dopamine neurons (data not shown).  
Table 1. Firing rate and spike distribution of dopamine neurons in the VTA
Controls Kynurenine 4-chlorokynurenine
(5 mg/kg; s.c., 60 min) (90 mg/kg/day; s.c., for six days)
n = 15 n = 9 n = 13
Firing rate, Hz 4.0 ± 0.2 5.0 ± 0.2** 5.1 ± 0.2**
Mean % spikes in burst 26.7 ± 2.8 40.2 ± 4.0++ 43.1 ± 3.0+++
Cells found per track 1.5 ± 0.2 2.1 ± 0.2 2.8 ± 0.4*
Intravenous pretreatment (1-3.5 h) with kynurenine (200 mg/kg, i.p.) or 4-Cl-Kyn (25 mg/kg, i.p.). Values 
represent means ±SEM from control rats (n=13) and rats treated with kynurenine (n=9) or 4-Cl-KYN (n=8). 
*P<0.05, **P<0.01 vs. corresponding control value (Mann-Whitney U-test). ++ P<0.01, +++ P<0.001 vs. 
corresponding control value (Wilcoxon signed rank test). 
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Figure 2. Time course depicting the increase in firing rate of VTA dopamine neurons after administration of 
SDZ 220-581(10 mg/kg, i.v., n = 4–7). **P < 0.01, ***P < 0.001 vs. corresponding control value (Mann-
Whitney U-test) 
 
Administration of the α7nACh receptor antagonist MLA (0.5–4 mg/kg, i.v) did not significantly 
change the firing rate or percent burst firing of VTA dopamine neurons (Figure 3b). However, a 
high dose of MLA (6 mg/kg) given i.p. significantly decreased firing rate and per cent burst firing 
of VTA dopamine neurons 10 min after administration (Figure 3c). 
The results of the present study show that the excitatory effects on VTA dopamine neurons 
observed in rats with elevated levels of KYNA (by administration of kynurenine) were mimicked 
by administration of 4-CL-KYN and SDZ but not MLA. In consonance with a recent study 
(Wang et al., 2006) intravenous administration of MLA in various doses up to 4 mg/kg failed to 
alter firing rate or burst firing activity of VTA dopamine neurons. However, when the drug was 
injected i.p. in a high dose (6 mg/kg), a significant decrease in firing was observed. These data 
are in analogy with the excitatory action on VTA dopamine neurons observed by galantamine, an 
α7nACh receptor agonist (Schilstrom et al., 2007). Thus, the α7nACh receptor antagonistic 
action by KYNA appears highly unlikely to participate in the increase in firing rate and burst 
firing activity of VTA dopamine neurons.  
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Figure 3. Extracellular recording from a dopamine neuron in the VTA showing the effect on firing rate by 
(a) SDZ 220-581 (1.25 + 1.25 + 2.5 + 5 mg/kg, injected i.v. at arrows), (b) MLA (0.5 + 0.5 + 1 + 2 mg/kg, 
injected i.v. at arrows) and (c) MLA (6 mg/kg, injected i.p. at arrow) 
 
Altogether, the results of the present study clearly show that the excitatory effect on VTA 
dopamine neurons by elevated levels of KYNA is mediated via blockade of the NMDA receptor. 
In support of the hypothesis that KYNA functions through the glycine-site of the NMDA receptor 
to excite VTA dopamine neurons is the previously reported finding that the KYNA-induced 
increase in firing could be restored following administration of D-cycloserine, a partial agonist at 
the glycine-site of the NMDA receptor (Erhardt and Engberg, 2002).  
Further, 7-Cl-KYNA a selective antagonist at the glycine-site of the NMDA without activity on 
the α7nACh receptor, produces the same magnitude of response of VTA dopamine neurons as 
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KYNA at equipotent concentrations. The excitatory action of VTA dopamine neurons by SDZ 
220-581, a competitive antagonist at the glutamate recognition-site of the NMDA receptor, 
principally indicates that the well-known ability of KYNA to block also this site could participate 
in its excitatory effects on VTA dopamine neurons, although relatively high concentrations of 
endogenous brain KYNA would be required. The somewhat paradoxical increase in firing rate 
and burst firing activity of midbrain dopamine neurons following elevated KYNA levels, has 
been suggested to be related to inhibition of a tonic GABAergic input that normally dampens 
neuronal activity of these neurons (Erhardt and Engberg, 2002). 
 
4.2     PAPER II: ELEVATED LEVELS OF KYNURENIC ACID CHANGE THE 
DOPAMINERGIC RESPONSE TO AMPHETAMINE: IMPLICATIONS FOR 
SCHIZOPHRENIA  
The dopamine (dopamine) hypothesis of schizophrenia suggests that an enhanced dopaminergic 
transmission in brain limbic areas causes positive symptoms of the disorder, e.g. delusions and 
hallucinations. Although clinical support of the dopamine hypothesis has been sparse, positron 
emission tomography (PET) studies have revealed an abnormal, excessive dopamine release 
following administration of amphetamine in untreated patients with schizophrenia (Abi-Dargham 
et al., 1998; Laruelle and Abi-Dargham, 1999; Laruelle et al., 1996; Breier et al., 1997).  
Amphetamine enters the brain where it increases extracellular dopamine. The large amount of 
dopamine efflux generates a negative feedback loop, leading to inhibition of cell firing in 
dopamine neurons (White, 1996).  In study II, the aim was to investigate the amphetamine-
induced effects on terminal dopamine release as well as on neuronal dopaminergic firing under 
conditions of acutely and subchronically elevated levels of brain KYNA. Hypothetically, if 
elevated levels of KYNA are one of the biological causes behind schizophrenia it might be a 
chronic condition. Kynurenine, the immediate precursor of KYNA, was administered to rats in a 
single-dose or subchronically via osmotic mini-pumps. The amphetamine-induced effects on 
dopamine transmission following elevated levels of brain KYNA were investigated, using in vivo 
extracellular single cell recordings of dopamine neurons in the VTA of anesthetized male 
Sprague Dawley rats. Also measurement of dopamine levels in the nucleus accumbens of awake, 
free moving rats were performed. 
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4.2.1  Effects on dopamine release following amphetamine administration 
Rats were given a single dose (5 mg/kg, s.c) or subchronic administration (90 mg/kg/d for six 
days, s.c, minipumps) of L-kynurenine, in order to increase KYNA brain levels. A single dose of 
kynurenine enhanced brain KYNA levels 3-fold, whereas subchronic treatment with kynurenine 
was associated with a 2-fold increase in brain KYNA levels at day 6 compared to saline treated 
control rats (Table 2).  
 
 
 
The extracellular dopamine levels in nucleus accumbens were measured by microdialysis and 
HPLC with electrochemical detektion. Data are presented as percent of baseline levels. The 
amphetamine-induced release of nucleus accumbens dopamine is summarized in figure 4. 
Systemic administration of amphetamine (2 mg/kg i.p.) was associated with a marked increase in 
dopamine release in the nucleus accumbens in control rats as well as in rats pretreated with a 
single dose of kynurenine (60 min prior to administration of amphetamine).  
Maximal increase in dopamine release was obtained 60 min after the amphetamine injection 
(+374% in control rats and +461% in rats pretreated with a single dose of kynurenine) but 
showed no significant difference. Administration of amphetamine to rats subchronically treated 
with kynurenine was associated with a potentiated extracellular dopamine efflux. This effect 
reached its maximum 60 min after the amphetamine injection (+814%) and was significantly 
enhanced compared to control rats. 
Table 2. Whole brain concentrations of kynurenic acid (nM)
Controls Acute kynurenine Subchronic kynurenine
(5 mg/kg; s.c., 60 min) (90 mg/kg/day; s.c., for six days)
n = 15 n = 9 n = 13
Kynurenic Acid (nM) 40.6 ± 8.1*66.1 ± 9.0***20.7 ± 3.5
Values represent mean±SEM. Statistics: *p<0.05, ***p<0.001 vs. controls (Kruskal-Wallis analysis of variance 
followed by Mann-Whitney U-test).
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Figure 4. Effects of amphetamine (2 mg/kg i.p.) administration dopamine output in the nucleus accumbens 
in awake, freely moving rats. Each point represents the mean ±S.E.M percent of baseline (n=4-13). *p<0.05  
**p<0.01  ***p<0.001 compared to pre-drug value (one way ANOVA followed Bonferroni multiple 
comparison test); + p<0.05 ++ p<0.001 between-group comparisons (two-way ANOVA for repeated 
measurements (time x treatment) followed by Bonferroni post-hoc tests).  
 
 
These results show that subchronically, but not acutely, elevated levels of brain KYNA potentiate 
the amphetamine induced dopamine response in nucleus accumbens. The enhanced dopamine 
response following subchronic administration indicates that enhanced KYNA levels in the rat 
brain produces alterations in the dopamine system, leading to amphetamine-induced 
hyperresponsiveness, comparable to patients with schizophrenia (Abi-Dargham et al., 1998; 
Laruelle and Abi-Dargham, 1999; Laruelle et al., 1996; Breier et al., 1997). In line with previous 
studies (Rassoulpour et al., 2005), systemic administration of 5 mg/kg L-kynurenine s.c., was 
associated with a trend towards reduced (25%) striatal dopamine output.  
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4.2.2   Amphetamine effects on the firing activity of dopamine neurons 
Firing activity and burst frequency of VTA dopamine neurons in rats pretreated with saline, a 
single dose of kynurenine (5 mg/kg s.c., 60 min) or with subchronic administration of kynurenine 
(90 mg/kg.d at day of surgery for 6 d) or saline  was examined following increasing doses of 
amphetamine. No differences in response between the naive control groups and the groups treated 
with saline for 6 d were observed in either of the tested parameters. For ease of presentation, all 
control data presented, were thus pooled into one control group.  A previous study demonstrates a 
relationship between basal firing of a single VTA dopamine neuron and the responsiveness of this 
neuron to amphetamine (White and Wang, 1984). Therefore, only recordings from dopamine 
neurons with similar frequency and burst firing activity within the groups were included. The 
effects of elevated brain KYNA levels on spontaneous firing rate and spike distribution are 
demonstrated in table 3. 
 
                
 
A single dose of 5 mg/kg L-kynurenine increased burst firing activity but did not change the 
firing rate of VTA dopamine neurons. Subchronic (90 mg/kg/day, s.c., for six days) pretreatment 
increased both firing rate and burst firing activity, in agreement with previous observations. 
Systemic administration of amphetamine was found to dose-dependently reduce firing rate and 
percent burst firing activity of VTA dopamine neurons. In control rats, the firing rate of nine 
VTA dopamine neurons out of 13 was totally suppressed following administration of 1.6 mg/kg 
Controls Acute kynurenine Subchronic kynurenine
(5 mg/kg; s.c., 60 min)        (90 mg/kg/day; s.c., for six days)
(33 neurons) (32 neurons) (19 neurons)
4.3 ± 0.3 4.8 ± 0.4 6.1 ± 0.4**
19.7 ± 39 37.2 ± 5.9* 37.9 ± 7.0*Mean % burst firing
Values represent mean±SEM from 24 control rats, 11 rats treated with acute kynurenine and 13 rats 
subchronically treated with kynurenine. Statistics: *p<0.05, **p<0.01 vs. corresponding control value (Kruskal-
Wallis analysis of variance followed by Mann-Whitney U-test).
Table 3. Effects of kynurenine on the firing rate and spike distribution of DA neurons in the VTA
Firing rate (Hz)
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amphetamine (Figs 2, 3a). The dopamine neurons still firing following administration of 1.6 
mg/kg amphetamine were quiescent after administration of 3.2 mg/kg (two neurons) or 6.4 mg/kg 
(two neurons). Rats pretreated with a single dose of kynurenine (5 mg/kg s.c., 60 min) did not 
change the inhibitory action of amphetamine (Fig 2). In rats with subchronically administered 
kynurenine (90 mg/kg.d at day of surgery for 6 d), larger doses of amphetamine were required to 
induce inhibition of firing rate and percent burst firing activity (Figure 5, 6b). Thus, 1,6 mg/kg 
amphetamine was not able to totally suppress firing in any dopamine neuron recorded from in 
these rats. Following 12.8 mg/kg amphetamine two neurons were still firing and bursting, one of 
them even at the dose 25.6 mg/kg and this neuron was not quiescent until apomorphine (100 mg/ 
kg i.v.) was administered. 
 
 
 
 
 
 
 
 
Figure 5. Cumulative dose-response 
curves illustrating the action of 
intravenously administered 
amphetamine on (a) the firing rate, 
and (b) the burst firing activity of 
VTA dopamine neurons in control 
rats and kynurenine treated rats, 
either a single dose or subchronically. 
Each point represents the mean 
±SEM obtained from 8-15 neurons. 
*p<0.05, between-group comparisons 
(Kruskal-Wallis analysis of variance 
followed by Mann-Whitney u test). 
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Figure 6. Extracellullar single recordings from dopamine neurons in the VTA following intravenous 
administration of D-amphetmine in cumulative doses (0.2+0.2+0.4+0.8+1.6+3.2 mg/kg at arrows) in (a) a 
control rat, and (b) a rat after subchronic treatment with kynurenine (90 mg/kg.d s.c., for 6 d). 
 
5   GENERAL DISCUSSION 
 
The major findings of the present thesis are that subchronic treatment with kynurenine, in contrast 
to a single dose of the compound, enhances the amphetamine-induced dopamine release in the rat 
nucleus accumbens. Given the augmented effect of amphetamine on dopamine neurotransmission 
seen in patients with schizophrenia (Abi-Dargham et al., 1998; Laruelle and Abi-Dargham, 1999; 
Laruelle et al., 1996; Breier et al., 1997), the results suggest that hypoglutamatergia, here induced 
by elevated levels of KYNA, may resemble a state similar to what is proposed in patients with 
schizophrenia. A rational explanation for the potentiated dopamine release may be an attenuated 
effect of amphetamine to inhibit firing of VTA dopamine neurons, in a situation of 
subchronically elevated brain KYNA.  
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A question of importance is whether the effects of KYNA are mediated via glutamatergic or 
cholinergic neurotransmission since KYNA is able to antagonize both the glycine site of the 
NMDA receptor and the α7nACh receptor at low concentrations. Here the excitatory effects on 
VTA dopamine neurons observed in rats with elevated levels of KYNA, were mimicked by 
pretreatment with the NMDA receptor antagonist SDZ, as well as with 4-Cl-KYN, which in situ 
is transformed to 7-Cl-KYNA, a specific antagonist at the glycine site of the NMDA receptor. 
The excitatory actions on VTA dopamine neurons by elevated KYNA levels are in accordance 
with the effects of other NMDA receptor antagonists. Thus, systemic administration of both 
noncompetitive NMDA receptor antagonists, such as PCP and MK 801 (French et al., 1991, 
1993; Zhang et al., 1992) as well as antagonists at the D-serine/glycine-site of the NMDA 
receptor, e.g. L-701,324 (Schwieler et al., 2006), is associated with increased firing of midbrain 
dopamine neurons. In contrast, blockade of the α7nACh receptor was rather associated with 
decreased firing of VTA dopamine neurons. These results provide strong evidence that KYNA 
increases VTA dopamine firing, primarily through glutamatergic- rather than cholinergic 
mechanisms.  
In conclusion, subchronic elevation of endogenous rat brain KYNA induces a markedly enhanced 
amphetamine-provoked dopamine release and hereby resembles the enhanced response to 
amphetamine seen in patients with schizophrenia (Abi-Dargham et al., 1998; Laruelle and Abi-
Dargham, 1999; Laruelle et al., 1996; Breier et al., 1997). Although the underlying mechanisms 
need to be more thoroughly investigated, a reduced responsiveness of VTA dopamine neurons 
toward the inhibitory action of amphetamine might partly explain the excessive dopamine efflux. 
Given the similarities in amphetamine response between patients with schizophrenia and rats with 
subchronically elevated levels of KYNA, one may propose that the latter condition may serve as 
a possible animal model of schizophrenia.   
Clearly, the kynurenine pathway has evolved to serve important regulatory functions in the 
mammalian brain and the current findings may serve to increase our understanding regarding the 
modulation of neuronal activity of midbrain dopamine neurons. The present results may also 
assist to open up novel perspectives and tools regarding the pharmacological treatment of 
schizophrenia and other dopamine-related diseases.  
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